{
    "cancelStatus": "0",
    "licStatus": "1",
    "cancelDate": null,
    "cancelReason": [],
    "otherCancelReason": "",
    "licid": "60001110",
    "licUnit": "1",
    "validDate": "2029-08-21 00:00:00.000",
    "issueDate": "2019-08-21 00:00:00.000",
    "oriIssueDate": null,
    "licKind": "04",
    "oldLicid": null,
    "certNo": "DHA06000111004",
    "prodNameC": "康癌停凍晶注射劑150毫克",
    "prodNameE": "KANJINTI Powder for concentrate for solution for infusion 150mg",
    "indicationsName": [
        "一、Kanjinti應使用於下列HER2過度表現或HER2基因amplification之早期乳癌、轉移性乳癌病人，說明：\r\n1.早期乳癌(EBC)：\r\n(1) 經外科手術、化學療法(術前或術後)之輔助療法。(2) 以doxorubicin與 cyclophosphamide治療，再合併paclitaxel或docetaxel之輔助療法。(3) 與docetaxel及carboplatin併用之輔助療法。(4) 術前與化學療法併用和術後之輔助療法使用於治療局部晚期(包括炎症)乳癌或腫瘤(直徑>2厘米)。\r\n2.轉移性乳癌(MBC)：\r\n(1) 單獨使用於曾接受過一次(含)以上化學療法之轉移性乳癌；除非病人不適合使用anthracycline或taxane，否則先前之化學治療應至少包括anthracycline或taxane。使用於荷爾蒙療法失敗之荷爾蒙受體陽性之病人，除非病人不適用荷爾蒙療法。(2) 與paclitaxel或docetaxel併用於未曾接受過化學療法之轉移性乳癌。(3) 與芳香環酶抑制劑併用於荷爾蒙受體陽性之轉移性乳癌。\r\n二、轉移性胃癌(mGC)：Kanjinti合併capecitabine (或5-fluorouracil)及cisplatin適用於未曾接受過化學治療之HER2過度表現轉移性胃腺癌(或胃食道接合處腺癌)的治療。說明：\r\n(1) HER2過度表現之檢測方法須經衛生主管機關核准(用於胃癌之檢驗)，請參照相關檢測套組仿單中適應症，確效(validation)及效能(performance)之敘述。另請參照本仿單[轉移性胃癌]之敘述。\r\n(2) 樞紐試驗確認療效僅顯現於有較高HER2蛋白表現(IHC2+\/FISH+或IHC3+)之族群。HER2次族群分析結果顯示，HER2蛋白表現較低(IHC 0\/FISH+: HR 0.92; IHC1+\/FISH+: HR 1.24)的族群的療效總體提升不高，反之，HER2蛋白表現較高(IHC2+\/FISH+: HR 0.75; IHC 3+\/FISH+: HR 0.58)的族群的療效總體提升較高。"
    ],
    "does": "2243",
    "packageUnit": [
        {
            "packageSpec": "150mg",
            "packageUnit": "L2"
        },
        {
            "packageSpec": "100支以下",
            "packageUnit": "03"
        }
    ],
    "medMCode": "05",
    "maMedCode": "",
    "medDCode": "D",
    "mainCategory": "D",
    "drBaseId": "1720E867-33AA-4AFD-B747-0F59E2A98D1C",
    "subCategory": [],
    "ingredientsDesc": [
        "Trastuzumab"
    ],
    "restraintItemsCode": [
        "02",
        "07",
        "1D",
        "91"
    ],
    "applicantName": "台灣安進藥品有限公司 ",
    "applicantAddr": "臺北市信義區松仁路100號13樓之1、之2",
    "medClass": null,
    "efficacy": " ",
    "mdFormat": null,
    "productAnnotation": "",
    "mdKind": [],
    "monitorDate": "2024-08-21",
    "licidNew": null,
    "licidOld": null,
    "factoryDtoList": [
        {
            "id": "F427736B-3ED1-4D03-91A7-F75F009CE652",
            "factoryCode": "1",
            "factoryName": "Amgen Technology (Ireland) Unlimited Company",
            "factoryAddr": "Pottery Road, Dun Laoghaire, Co., Dublin, Ireland",
            "factoryCompanyAddr": "",
            "countryCode": "IE",
            "processCode": [
                {
                    "value": "66",
                    "name": "成品製造廠"
                }
            ],
            "processCodeStr": "66;成品製造廠",
            "factoryKind": "M",
            "factoryNo": "FIE0040100",
            "factoryInfo": null,
            "qsd": null,
            "qsdList": [],
            "factoryMadeIn": null
        },
        {
            "id": "EB8A8319-5A22-4705-9C99-22DA134846E0",
            "factoryCode": "2",
            "factoryName": "AMGEN MANUFACTURING LIMITED LLC",
            "factoryAddr": "STATE ROAD 31, KM 24.6 JUNCOS, PUERTO RICO 00777-4060",
            "factoryCompanyAddr": null,
            "countryCode": "PR",
            "processCode": [
                {
                    "value": "1A",
                    "name": "二級包裝廠"
                }
            ],
            "processCodeStr": "1A;二級包裝廠",
            "factoryKind": "M",
            "factoryNo": "FPR0062100",
            "factoryInfo": null,
            "qsd": null,
            "qsdList": [],
            "factoryMadeIn": null
        },
        {
            "id": "7818D689-A927-4FE2-B585-7313FC67FDD3",
            "factoryCode": "2",
            "factoryName": "IMMUNEX RHODE ISLAND CORPORATION",
            "factoryAddr": "40 TECHNOLOGY WAY, WEST GREENWICH RHODE ISLAND 02817, USA",
            "factoryCompanyAddr": "",
            "countryCode": "US",
            "processCode": [
                {
                    "value": "1K",
                    "name": "原料藥製造廠"
                }
            ],
            "processCodeStr": "1K;原料藥製造廠",
            "factoryKind": "M",
            "factoryNo": "FUS0866000",
            "factoryInfo": null,
            "qsd": null,
            "qsdList": [],
            "factoryMadeIn": null
        }
    ],
    "ingredientsDtoList": [
        {
            "ingredientsKind": "1",
            "ingredientsCode": "1013004800",
            "ingredientsName": "Trastuzumab",
            "ingredientsDesc": "Trastuzumab",
            "concentDesc": "",
            "concent": "150.0000",
            "concentUnit": "001",
            "seq": "1",
            "prescription_seq": "1",
            "prescription_Kind": "1"
        }
    ],
    "authDtoList": [],
    "iomDtoList": [],
    "changeDtoList": [],
    "atcList": [
        {
            "isMain": "1",
            "atcCode": "L01FD01"
        }
    ],
    "licBaseId": "85443322-AA1E-4220-A09F-0A0A5872E818"
}